Class / Patent application number | Description | Number of patent applications / Date published |
514500400 | Iron affecting | 15 |
20110053837 | Mineral-peptide chelates - The present invention provides a mineral-peptide chelate comprising a peptide consisting of 2˜18 amino acids and a mineral chelated to the peptide, wherein the peptide can be a hydrolysate obtained by hydrolyzing soybean or other protein materials with proteases, or a product obtained by hydrolyzing soybean or other protein material with proteases and fermentation. The mineral-peptide chelate of the present invention may further comprise a carrier which covers the peptide and the mineral which is chelated to the peptide. | 03-03-2011 |
20120040894 | Mini-Hepcidin Peptides and Methods of Using thereof - Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof. | 02-16-2012 |
20120094900 | SENSITIZING AGENTS FOR CANCER THERAPY, METHODS OF USE AND METHODS FOR THE IDENTIFICATION THEREOF - There is provided herein methods, compounds and methods for identifying compounds, for sensitizing a subject with cancer to a cancer therapy by inhibiting or down-regulating UROD. | 04-19-2012 |
20130072428 | Methods and Compounds Regulating the Erythroid Response to Iron Deficiency - The present invention discloses the signaling pathway involved erythroid repression by iron deficiency. Further disclosed is anon-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakaryocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation. | 03-21-2013 |
20130203662 | Mini-Hepcidin Peptides and Methods of Using Thereof - Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof. | 08-08-2013 |
20140057840 | ANTI-ANDROGENIC AGENT, SEBUM SECRETION BLOCKER, HAIR GROWTH STIMULANT, AND FOOD OR BEVERAGE - Provision of an anti-androgenic agent which has a strong anti-androgenic action, is free of side effects and very safe, and a sebum secretion blocker and a hair growth stimulant containing the anti-androgenic agent as an active ingredient. Provided are the anti-androgenic agent comprising lactoferrin, the sebum secretion blocker containing the anti-androgenic agent as an active ingredient, the hair growth stimulant containing the anti-androgenic agent as an active ingredient, and a food or drink product comprising the anti-androgenic agent containing lactoferrin as an active ingredient. | 02-27-2014 |
20140121156 | NUTRITIONAL APPROACH TO THE CONTROL OF ANEMIA, DIABETES AND OTHER DISEASES OR CONDITIONS AND PREVENTION OF ASSOCIATED COMORBID STATES WITH THE USE OF ERGOTHIONEINE - Nutritional products, compositions, pharmaceutical preparations and methods of use are disclosed for the prevention, suppression and treatment of anemia and/or diabetes and its various associated comorbidities. Uses of Ergothioneine to neutralize free radicals and/or cytokines, reduce oxidative stress, prevent inflammation, stimulate red blood cell production with increased levels of hemoglobin, and/or stabilize iron in its normal 2 | 05-01-2014 |
20140336110 | Modified Mini-Hepcidin Peptides and Methods of Using Thereof - Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof. | 11-13-2014 |
20150072927 | METHODS AND COMPOSITIONS TO REGULATE HEPCIDIN EXPRESSION - The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders. | 03-12-2015 |
20160051556 | Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression - The present invention relates to an isolated EGF receptor agonist for use in the treatment of chronic liver diseases associated with a low hepcidin expression such as alcoholic liver disease, chronic hepatitis C, or genetic hemochromatosis. | 02-25-2016 |
20160166638 | LACTOFERRIN-OSTEOPONTIN-IRON COMPLEX | 06-16-2016 |
20160166649 | USE OF HEPCIDIN AS A REGULATOR OF IRON HOMEOSTASIS | 06-16-2016 |
20160200765 | Modified Mini-Hepcidin Peptides and Methods of Using Thereof | 07-14-2016 |
20170231938 | PROTECTIVE METALLOTHIONEIN ANALOG COMPOUNDS, THEIR COMPOSITIONS AND USE THEREOF IN THE TREATMENT OF PATHOGENIC DISEASES | 08-17-2017 |
20180021405 | NUTRITIONAL APPROACH TO THE CONTROL OF ANEMIA, DIABETES AND OTHER DISEASES OR CONDITIONS AND PREVENTION OF ASSOCIATED COMORBID STATES WITH THE USE OF ERGOTHIONEINE | 01-25-2018 |